REPONEX PHARMACEUTICALS A/S: Financial statements 2024
CVR: 30082346
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
REPONEX PHARMACEUTICALS A/S (CVR 30082346) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 0 and a net result of DKK -11,943,000 compared with EUR -14,346,000 the year before. Equity in the 2024 report amounted to DKK -8,785,000.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -11,943,000
- Equity
- DKK -8,785,000
- Total Assets
- DKK 3,631,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 0 | 0 | -11.9M | -8.8M | - |
| 2023 | 0 EUR | 0 EUR | -14.3M EUR | 16.8M EUR | - |
| 2022 | - | - | -10.2M | 17.4M | - |
| 2021 | 0 | 0 | -9.9M | 27.4M | - |
| 2020 | 0 | 0 | -1.5M | 13.4M | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
REPONEX PHARMACEUTICALS A/S has published its annual report for 2023. Revenue came to DKK 0, and the net result was DKK -14,346,000.
About REPONEX PHARMACEUTICALS A/S
REPONEX PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named REPONEX PHARMACEUTICALS ApS and TRIFOILIUM ApS. The management consists of Christian Henrik Tange. The board consists of Christian Vinding Thomsen (chair), Troels Peter Troelsen and Charlotte Pahl. The company is owned by Pharma Equity Group A/S. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -6,570,000 compared with DKK -11,943,000 the year before. Equity in the 2025 report amounted to DKK 4,645,000.